Synthetic Biologics Inc. (SYN) and Its Peers Financial Results Comparison

Synthetic Biologics Inc. (NYSEAMERICAN:SYN) is a company in the Biotechnology industry and that’s how we compare it to its peers. The comparing will be based on the risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation.

Institutional & Insider Ownership

Synthetic Biologics Inc. has 6.6% of its shares owned by institutional investors & an average of 50.88% institutional ownership for its rivals. On other hand Synthetic Biologics Inc. has 0.11% of its shares owned by company insiders & an average of 8.18% insiders ownership for its peers.


Table 1 has Synthetic Biologics Inc. and its peers’ return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Synthetic Biologics Inc. 0.00% 203.60% -60.10%
Industry Average 1,464.25% 88.44% 21.62%

Valuation and Earnings

In next table we are comparing Synthetic Biologics Inc. and its peers’ net income, gross revenue and valuation.

Net Income Gross Revenue Price/Earnings Ratio
Synthetic Biologics Inc. 7.59M N/A 0.18
Industry Average 34.08M 2.33M 58.78

With presently lower P/E ratio Synthetic Biologics Inc. is more affordable than its rivals.

Analyst Ratings

Table 3 shows summary of recent ratings for Synthetic Biologics Inc. and its peers.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Synthetic Biologics Inc. 0 0 0 0.00
Industry Average 1.17 1.78 2.01 2.68

The rivals have a potential upside of 173.20%.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of Synthetic Biologics Inc. and its rivals.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Synthetic Biologics Inc. -7.93% -21.37% -74.08% -91.3% -96.7% -96.06%
Industry Average 9.08% 15.16% 32.92% 41.89% 74.81% 65.27%

For the past year Synthetic Biologics Inc. has -96.06% weaker performance while Synthetic Biologics Inc.’s peers have 65.27% stronger performance.


The Current Ratio and a Quick Ratio of Synthetic Biologics Inc. are 2.6 and 2.6. Competitively, Synthetic Biologics Inc.’s rivals have 7.68 and 7.52 for Current and Quick Ratio. Synthetic Biologics Inc.’s peers have better ability to pay short and long-term obligations than Synthetic Biologics Inc.

Risk & Volatility

Synthetic Biologics Inc. has a beta of 2.28 and its 128.00% more volatile than S&P 500. Competitively, Synthetic Biologics Inc.’s rivals are 70.08% more volatile than S&P 500, because of the 1.70 beta.


Synthetic Biologics Inc. does not pay a dividend.


Synthetic Biologics Inc.’s peers beat Synthetic Biologics Inc. on 5 of the 5 factors.

Synthetic Biologics, Inc., a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients in the United States. Its lead product candidates in Phase III development include SYN-010, which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase) that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection (CDI), antibiotic-associated diarrhea (AAD), and the emergence of antimicrobial resistance (AMR). The company is also developing SYN-007 and SYN-006 for the prevention of CDI and AAD; SYN-005, a monoclonal antibody therapy for the prevention and treatment of pertussis; SYN-200 for the treatment of phenylketonuria; and SYN-020, an oral dosage form of intestinal alkaline phosphatase. It has collaboration agreements with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetic Biologics, Inc. in February 2012. Synthetic Biologics, Inc. was founded in 2001 and is headquartered in Rockville, Maryland.